

Lovastatin Reduces Stemness via Epigenetic Reprogramming of *BMP2* and *GATA2* in Human Endometrium and Endometriosis

Mahdieh Taghizadeh, M.Sc., Mehrdad Noruzinia, M.D., Ph.D.*

Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

*Corresponding Address: P.O.Box: 11115-331, Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Email: noruzinia@modares.ac.ir

Received: 23/Feb/2016, Accepted: 22/Jun/2016

Abstract

Objective: The stem cell theory in the endometriosis provides an advanced avenue of targeting these cells as a novel therapy to eliminate endometriosis. In this regard, studies showed that lovastatin alters the cells from a stem-like state to more differentiated condition and reduces stemness. The aim of this study was to investigate whether lovastatin treatment could influence expression and methylation patterns of genes regulating differentiation of endometrial mesenchymal stem cells (eMSCs) such as *BMP2*, *GATA2* and *RUNX2* as well as eMSCs markers.

Materials and Methods: In this experimental investigation, MSCs were isolated from endometrial and endometriotic tissues and treated with lovastatin and decitabin. To investigate the osteogenic and adipogenic differentiation of eMSCs treated with the different concentration of lovastatin and decitabin, *BMP2*, *RUNX2* and *GATA2* expressions were measured by real-time polymerase chain reaction (PCR). To determine involvement of DNA methylation in *BMP2* and *GATA2* gene regulations of eMSCs, we used quantitative Methylation Specific PCR (qMSP) for evaluation of the *BMP2* promoter status and differentially methylated region of *GATA2* exon 4.

Results: In the present study, treatment with lovastatin increased expression of *BMP2* and *RUNX2* and induced *BMP2* promoter demethylation. We also demonstrated that lovastatin treatment down-regulated *GATA2* expression via inducing methylation. In addition, the results indicated that CD146 cell marker was decreased to 53% in response to lovastatin treatment compared to untreated group.

Conclusion: These findings indicated that lovastatin treatment could increase the differentiation of eMSCs toward osteogenic and adipogenic lineages, while it decreased expression of eMSCs markers and subsequently reduced the stemness.

Keywords: Endometriosis, Lovastatin, Epigenetics, Stemness

Cell Journal(Yakhteh), Vol 19, No 1, Apr-Jun (Spring) 2017, Pages: 50-64

Citation: Taghizadeh M, Noruzinia M. Lovastatin reduces stemness via epigenetic reprogramming of *BMP2* and *GATA2* in human endometrium and endometriosis. Cell J. 2017; 19(1): 50-64

Introduction

Endometriosis is a non-cancerous gynecological disorder characterized by the presence of endometrial glands and stromal cells outside the uterine cavity (1). It can be considered as the obvious cause of disability in the women with the reproductive ages affecting 6-12% of the asymptomatic women, approximately 71-78% of women suffering chronic pelvic pain and up to 5%

of the infertile women (2-4).

Pathogenesis of endometriosis includes metaplastic alteration of epithelial cells in the peritoneal surface (5), retrograde of endometrial cells, immunological insufficiency, genetics and epigenetics (6, 7), as well as hormone disruption (8). Highly embraced hypothesis for the endometriosis development is retrograde

menstruation (9). It was found that women with endometriosis have a considerable amount of basalis endometrium in their menstrual debris than those without endometriosis (10), more likely because of the excessive uterine peristaltic contractions in women suffering this disease (11). The importance of basalis layer of endometrium in the endometriotic lesion development can be related to the large numbers of stem cells in this area (12). In this respect, some studies also revealed that the stem cell theory has a significant role in the endometriosis pathogenesis (13, 14).

In addition, recent medications were found to have severe side-effects for treating endometriosis. Therefore, topnotch and effective treatments for endometriosis are required. The main mode of action for all of the present medications in treating pains, associated with endometriosis, is mostly caused by suppression of the implants proliferation (15, 16). The theory of stem cell in endometriosis began the last advanced avenue in the targeting these cells as cutting-edge therapy (17).

In this respect, lovastatin shifts the cells from a stem-like state to more differentiated condition and reduces the stemness (18). Furthermore, lovastatin is effective in the suppression of cell proliferation and angiogenesis in an experimental model of endometriosis (19). In this line, lovastatin function via modulating DNA methyltransferase (DNMT) activity, altering methylation of gene promoters, and consequently regulating mRNA expression in the various malignancies (18, 20).

On the other hand, activity of DNMTs, the enzymes that catalyze addition of methyl groups to cytosine residues in DNA, is elevated in the ectopic endometrium compared to the normal control (21). DNMT inhibitors have profoundly been examined as the promising novel drugs for endometriosis treatment (22-24). Recently, decitabine and 5-azacytidine have been introduced into the clinical trial experiment (25), but it was found that DNMT inhibitors cause considerable toxicity. In addition, they interfere with protein translation procedure through incorporating into RNA (26,

27). Because of this reason, drugs like statins, demonstrating DNMT inhibitory function with no toxic side-effect, would open up a new horizon regarding the novel advancement in the disease treatment.

Some investigations revealed that lovastatin treatment leads to demethylation of the *BMP2* promoter, up-regulation of the *BMP2* mRNA and activation of BMP signaling pathway. Consequently, these alterations induce colorectal cancer (CRC) cell differentiation and reduce proliferation of the respective cells (18, 28).

Moreover, BMP pathway, particularly *BMP2* plays a crucial role in the pathogenesis of endometriosis (29). *BMP2*, a tumor growth factor (TGF) superfamily member, acts downstream of PGR and is essential for the stromal cell differentiation and decidualization in both mouse and human endometrium (30). Furthermore, Aghajanova et al. (31) found that *BMP-2* can promote osteogenic differentiation of the human endometrial stem cells.

In this study, we initially set out to determine (1) whether lovastatin treatment influences methylation status of the *BMP2* promoter as well as mRNA expression of the respective gene and (2) whether lovastatin can also alter the expression level of other genes playing pivotal role in differentiation and proliferation potential of endometrial mesenchymal stem cells (eMSCs), such as *GATA2* and *RUNX2* (32, 33). Additionally, we then evaluated the effects of lovastatin on the endometrial stem cell markers derived from the patient and normal individuals.

Materials and Methods

Patients

This experimental investigation was approved by the Institutional Review Board of the Faculty of Medicine at Tarbiat Modares University in Iran. Endometrial and endometriotic tissues were obtained from six patients (endometrial tissues from three patients; endometriosis samples from three patients) at Obstetric Gynecology Department of Sarem Women

Hospital (Tehran, Iran). The patients were undergone hysterectomy and laparoscopy for benign pathologies and written informed consent was also received from the participants. The surgery was performed irrespective of the day of patient's menstrual cycle. The exclusion criteria were any endometrial abnormality (e.g. polyps, hyperplasia or cancer), administration of the hormonal treatment and gonadotropin-releasing hormone (GnRH) agonist therapy. Additionally, this study was performed according to the Helsinki declaration.

Mesenchymal stem cells isolation and expansion

First, tissue was separated and washed with the phosphate-buffered saline (PBS). It was minced into the small pieces measuring 1 mm³ and digested with 1 mg/ml collagenase type I (Sigma, Germany) for 60 minutes at 37°C and centrifuged for 10 minutes at 500 g. Second, cells were plated in the 25 cm² tissue culture using Dulbecco's Modified Eagle's Medium (DMEM, Biowest, France) supplemented with 20% fetal bovine serum (FBS, Gibco, USA), 50 mg/ml of streptomycin and 50 U/ml of penicillin (Invitrogen, USA) at 37°C in 95% air and 5% CO₂. After that, when cultures reached at 80 to 90% confluence, eMSCs were trypsinized using trypsin EDTA 0.25% (Biowest, France) and then the media were replaced. For this study cells were treated with lovastatin and decitabin at the passage four.

Flow cytometry analysis

To characterize and quantify the expression of MSCs markers according to the surface molecular markers (34), flow cytometry analysis was performed. First, cells were detached with trypsin EDTA 25% at the end of third passage and washed with PBS by centrifugation (300 g, 5 minutes). After that, cells (1×10⁶ cells) were incubated with the monoclonal antibodies (e.g. CD90, CD44, CD146, CD45 and CD34) and the matched-isotype control for 30 minutes at 4°C. Finally, cell analysis was performed using Partec CyFlow® Space flow cytometer system (German Biotechnology Company, Germany) and the flowmax Software.

Osteogenic and adipogenic differentiation of endometrial mesenchymal stem cells

In order to perform the osteogenic and adipogenic differentiation, eMSCs were seeded at the density of 2×10⁴ cells/cm² in 24-well tissue culture plates and incubated in DMEM overnight at 37°C and 5% CO₂ until 80% confluency. Differentiation was carried out using osteogenic and adipogenic media according to the manufacturer's instructions. In this respect, osteogenic differentiation was induced using DMEM high glucose supplemented with 10% FBS, 10 nM dexamethasone, 10 mM β-glycerophosphate and 10 μM ascorbic acid 2-phosphates (both from Sigma) for 21 days. Additionally, adipogenic differentiation was carried out by culturing eMSCs in DMEM high glucose supplemented with 10% FBS, 1 μM dexamethasone, 10 μM ascorbic acid 2-phosphate and 200 μM indomethacin (both from Sigma) for 21 days. Three weeks later, osteogenic and adipogenic differentiations were confirmed by Alizarin Red and Oil Red (both from Sigma) staining, respectively (35).

MTT assay

First, eMSCs derived from the endometriotic tissues were seeded at the density of 1×10⁴ cells/cm² in a 24-well plate and cultured for 24 hours. Second, cells were treated with 1, 2 and 5 μM lovastatin diluted in dimethyl sulfoxide (DMSO), for 72 hours. Then, eMSCs were incubated with standard medium containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) with final concentration of 0.5 mg/ml (stock solution 5 mg/ml MTT in PBS) for 4 hours at 37°C. At the end of experiment, the medium was removed and 500 μl DMSO was added. Absorbance was evaluated at 540 nm in a 96-well plate using an Anthos 2020 Microplate Readers (Austria). Experiments were carried out in triplicate, from three independent experiments (36, 37).

Treatment of endometrial mesenchymal stem cells with lovastatin and decitabin

First, MSCs from the human endometrium and endometriosis were seeded at an initial density

of 60% confluence. They were then allowed to be attached overnight, and after that treated with lovastatin and decitabin (both from Sigma). According to the previous investigations (33, 38), MSCs were treated in the 1, 2 and 5 μM concentration of lovastatin for 72 hours, while these cells were treated in DMSO, as vehicle group. In addition, dose of 2 μM was used for decitabin treatment in the MSCs for 72 hours (39). After treatment, the cells were trypsinized and used for flow cytometry analysis, real-time polymerase chain reaction (PCR) and quantitative methylation specific PCR (qMSP).

RNA extraction and quantitative analysis by real-time polymerase chain reaction

First, total RNA was isolated from the eMSCs with High Pure RNA Isolation Kit (Roche, Germany) according to the manufacturer's protocol. Second, the purity of RNA was determined, by gel electrophoresis, photospectrometrically (ratio 260/280 nm), and by RT-PCR reactions. For each sample, 1 μg of RNA was used to generate cDNA with RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, USA). Then, quantitative reverse transcriptase PCR was carried out to determine the expression of genes encoding Bone Morphogenetic Protein2 (*BMP2*), GATA binding protein 2 (*GATA2*), Runt-related transcription factor (*RUNX2*), hypoxanthine phosphoribosyl transferase 1 (*HPRT1*) with StepOne™ Real-Time PCR system (Applied Biosystems, USA). Primers used for SYBR Green assay were:

BMP2

F: 5'-CCACCATGAAGAATCTTTGGAAGAAC-3'
R: 5'-TGATAAACTCCTCCGTGGGGA-3'

GATA2

F: 5'-GCTCGTTCCTGTTTCAGAAGGC-3'
R: 5'-CCATTCATCTTGTGGTAGAGGC-3'

RUNX2

F: 5'-CCCCACGACAACCGCACCAT-3'
R: 5'-CGCTCCGGCCCAAAATCTC-3' (40)

HPRT

F: 5'-GGTCCTTTTCACCAGCAAGCT-3'
R: 5'-TGACACTGGCAAAACAATGCA-3'.

HPRT values were used for normalization. PCR product length for *BMP2*, *GATA2*, *RUNX2* and *HPRT* primers was 101, 126, 289, and 94 bp, respectively. Gene expression was calculated using the $\Delta\Delta\text{Ct}$ method (41).

Sodium bisulfite treatment of genomic DNA

First, DNA was isolated from eMSCs using High Pure PCR Template Preparation Kit (Roche) as recommended by the manufacturer's instruction. Second, for sodium bisulfite treatment, 300 ng of DNA was denatured by 0.2 M NaOH for 10 minutes at 37°C in 50 ml total volume. Then, 30 μl of freshly prepared 10 mM hydroquinone (Merck, US) and 520 μl of 3.5 M sodium bisulfite (pH=5, Merck, US) were added to the samples. After that, each DNA sample was incubated at 50°C for 16 hours. Samples were also purified with Roche DNA purification columns based on the manufacturer's instruction and eluted in 200 μl of elution buffer. At last, samples were desulfonated by 0.3 M NaOH treatment for 5 minutes at 20°C. Finally, after ethanol precipitation, DNA was dissolved in 30 μl distilled water (42).

Quantitative Methylation Specific polymerase chain reaction

For analyzing *BMP2* promoter methylation, MethySYBR Method was performed with StepOne™ Real-Time PCR System (Applied Biosystems). In this study, according to the one-step MethySYBR method (43), the primers (BMP2-EXT-F and BMP2-EXT-R; product length=308) were used in the externally nested real time PCR amplified the target gene regardless of their methylation status. This was used as a reference control to normalize the proportion of methylated target alleles which were detected by the methylation specific primer pair (BMP2-FM and BMP2-RM, product length=113) between the samples. Each reaction contained 20-25 ng of bisulfite-treated DNA as a template, 10 ml 2x RealQ Master Mix amplicon and 500 nM of each forward and reverse primer (Table 1) in a total volume of 20 μl . For *BMP2*, real-time PCR thermocyclic conditions included an initial step of 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 30 seconds.

In this method, plasmid template was included as the control for calculation of methylation percentage of each sample. Methylated DNA level was calculated with $2^{-\Delta\Delta C_t}$ in which $\Delta\Delta C_t$ equals to $\Delta C_{t\text{ sample}} - \Delta C_{t\text{ plasmid}}$ (43). Furthermore, to evaluate the methylation status of *GATA2*, we performed qMSP using the primers directed against differentially methylated regions of exon 4 of *GATA2*. Briefly, primers were designed to determine either the methylated or unmethylated form of the sequence after the bisulfite converted sequences of the sense strand. Primer information is provided in Table 1. For *GATA2*, the thermocyclic conditions of real-time PCR included an initial denaturation step of 10 minute at 95°C, followed by 40 cycles of 95°C for 15 seconds and 57°C for 30 seconds. Additionally, the product length for the *GATA2*-Meth and *GATA2*-Unmeth primers was 139 bp.

Statistical analysis

Comparison of gene expressions, methylation values as well as cell viability tests between

samples were assessed with a two tailed student's t test using GraphPad Prism 6 software. Results were statistically significant at a $P < 0.05$.

Results

Isolation and characterization of endometrial mesenchymal stem cells

MSCs from human endometrium were isolated and cultured, while they predominantly had fibroblastic shape as expected (Fig.1A). To evaluate differentiation potential of eMSCs, induction to adipogenic and osteogenic lineage was performed *in vitro*. A potential for the differentiation to adipogenic lineage was confirmed through staining of lipid vacuoles by oil red (Fig.1B). Furthermore, osteogenic differentiation was detected through alizarin red staining of calcium deposits (Fig.1C). Flow cytometer analysis indicated that cells expressed the mesenchymal markers CD44 (94.60%), CD90 (94.33%) and CD146 (94.83%), but they lacked hematopoietic markers including CD45 (3.77%) and CD34 (5.40%) (Fig.1D-H).

Table 1: Primer sequences for qMSP analysis of *GATA2* and *BMP2*

Gene name	Primer sequences (5'-3')
<i>BMP2</i> -EXT	F: GTGTATTGGAGTAAGGTAGAGTGATG R: CCCAACCAATACTAACACACAACAAC
<i>BMP2</i> -FM	F: GGTTGTTTCGAGTTATGGGTCGC R: AAAACCAACGCCCGAAAAACGCG
<i>GATA2</i> -Ex4-Meth	F: TTCGCGTAGTTGTTGTTTTAGAC R: GAACCCAATACTCACCGTACG
<i>GATA2</i> -Ex4-Un	F: TTGTGTAGTTGTTGTTTTAGATGA R: ACAAACCAATACTCACCATACAC




Fig.1: Mesenchymal stem cells (MSCs) characterization. Human endometrial MSCs (eMSCs) exhibited, **A.** A fibroblast-like cell shape. These cells also represented successful, **B.** Adipogenic, **C.** Osteogenic differentiation potential, showing a positive signal for **D.** CD44 (94.60%), **E.** CD90 (94.33%), **F.** CD146 (94.83%) and no signal for **G.** CD45 (3.77%), and **H.** CD34 (5.40%) markers (n=3).

Lovastatin mediates up-regulation of *BMP2* and *RUNX2*

To investigate the effect of different lovastatin concentrations on *BMP2* and *RUNX2* mRNA expression, eMSCs were isolated from the patient and normal individuals and then were incubated for 72 hours with 2 and 5 μM concentrations of lovastatin. Relative expression amounts of *BMP2* in plates treated with the different concentrations of lovastatin, vehicle (DMSO) and 2 μM decitabin, as the positive control, are shown in Figure 2. In comparison with untreated control of both groups, relative expressions of *BMP2* at 2 μM lovastatin-treated eMSCs were 1.69 ± 0.26 and 2.22 ± 0.1 fold further than those of control eMSCs in the patients and normal groups, respectively. Statistical analysis showed a significant difference between 2 μM lovastatin and control in both groups ($P < 0.05$, Student's t test). Furthermore, *RUNX2* expression was markedly up-regulated in the plates treated with 2 and 5 μM of lovastatin as well as 2 μM decitabin in comparison with the untreated

control of patient group (2.58 ± 0.32 fold, 1.86 ± 0.22 fold and 2.26 ± 0.18 fold, respectively, $P < 0.05$ for 2 and 5 μM of lovastatin and $P < 0.01$ for 2 μM decitabin). *RUNX2* expression was also up-regulated in plates treated with 2 and 5 μM of lovastatin as well as 2 μM decitabin compared to the untreated control of normal group (3.35 ± 0.21 fold, 2.02 ± 0.10 fold and 2.12 ± 0.10 fold respectively, $P < 0.05$).

Lovastatin mediates down-regulation of *GATA2*

Following 2 μM lovastatin treatment, *GATA2* expression was slightly down-regulated, while the expression of *GATA2* was significantly decreased in response to 5 μM lovastatin treatment in comparison with the untreated control of patient group (Fig.3, 0.57 ± 0.14 fold, $P < 0.05$). On the other hand, *GATA2* expression at 2 μM statin-treated eMSCs were 1.75 ± 0.07 fold higher than those of the control eMSCs in normal (Fig.3, $P < 0.05$). There was also no significant difference in the expression levels of *GATA2* in response to 2 μM decitabin, compared to the untreated control of both groups.




Fig.2: *BMP2* and *RUNX2* expressions following the lovastatin treatment in endometrial mesenchymal stem cells (eMSCs) cultures of three patients and three normal individuals, detected by quantitative real-time polymerase chain reaction (RT-PCR). **A.** Relative expression of *BMP2* at 2 μM statin-treated eMSCs was 1.69 ± 0.26 and 2.22 ± 0.1 fold higher than those of control eMSCs in patient and normal groups, respectively ($P < 0.05$, Student's t test) and **B.** *RUNX2* expression was up-regulated in plates treated with 2 and 5 μM of lovastatin as well as 2 μM decitabin in comparison with untreated control of patient group (2.58 ± 0.32 fold, 1.86 ± 0.22 fold and 2.26 ± 0.18 fold respectively, $P < 0.05$ for 2 and 5 μM of lovastatin and $P < 0.01$ for 2 μM decitabin) and normal group (3.35 ± 0.21 fold, 2.02 ± 0.10 fold and 2.12 ± 0.10 fold respectively).

*, $P < 0.05$ and **, $P < 0.01$ in comparison to untreated control in each groups.




Fig.3: *GATA2* expression following the lovastatin treatment in endometrial mesenchymal stem cells (eMSCs) cultures of three patients and three normal individuals, detected by quantitative real-time polymerase chain reaction (RT-PCR). Relative expression of *GATA2* was decreased in response to 5 μM lovastatin treatment in comparison with untreated control of patient 0.57 ± 0.14 fold ($P < 0.05$). On the other hand, *GATA2* expression at 2 μM lovastatin-treated eMSCs was 1.75 ± 0.07 fold higher than those of control eMSCs in normal.

*, $P < 0.05$ in comparison to untreated control in each groups.

Lovastatin treatment leads to epigenetic modification of the *BMP2* and *GATA2*

To determine involvement of DNA methylation in the *BMP2* gene down-regulation of eMSCs treated with the different concentration of lovastatin, we used quantitative Methylation Specific PCR (qMSP) for the respective promoter status, starting 214 bp upstream of exon 1. This region contains a CpG island that methylated in the gastric and colorectal cancers (18, 44). As Figure 4A shows, lovastatin treatment induced demethylation of the *BMP2* promoter in eMSCs treated with 2 μM lovastatin for 72 hours. The qMSP results showed that *BMP2* promoter methylation was decreased from 28.2 to 7.6% in eMSCs after treatment with 2 μM lovastatin for 72 hours ($P < 0.05$, Student's t test).

We also performed qMSP for *GATA2* before and after lovastatin and decitabin treatments using the methylated and unmethylated primers directed against differentially methylated region of *GATA2* exon 4 (45). As Figure 4B shows, lovastatin treatment induced methylation of the differentially methylated region of *GATA2* exon 4 in eMSCs treated for 72 hours with 2 and 5 μM lovastatin. The qMSP results

showed that the *GATA2* exon 4 methylation was increased in eMSCs from 12.0 to 26.95 and 70.49% after treatment with 2 and 5 μM lovastatin for 72 hours, respectively ($P < 0.05$, Student's t test).




Fig.4: Quantitative methylation specific PCR (qMSP) analysis of *BMP2* promoter region and *GATA2* exon 4 in endometrial mesenchymal stem cells (eMSCs) treated with different concentration of lovastatin. **A.** qMSP results showed that *BMP2* promoter methylation was decreased from 28.2 to 7.6% after treatment with 2 μM of lovastatin for 72 hours ($P < 0.05$, Student's t test) and **B.** qMSP results showed that *GATA2* exon 4 methylation was increased from 12.0 to 26.95 and 70.49% after treatment with 2 and 5 μM of lovastatin for 72 hours, respectively.

*, $P < 0.05$ in comparison to untreated control in each groups.

No influence on the cell viability by lovastatin up to 5 μ M concentration

Changes in the cell viability could lead to a decrease in cell number and a low influence on cell therapy. In order to determine the effects of lovastatin (diluted in DMSO) and DMSO on eMSCs viability, cells were incubated with 1, 2 and 5 μ M lovastatin for 72 hours, and then, mitochondrial dehydrogenase activity was evaluated in the living cells by the MTT test (46). The cell viability in vehicle as well as treatment group was observed in approximately 80% of cells in comparison to the untreated group. However, statistical analysis showed a significant difference at the enzyme level under 2 and 5 μ M lovastatin and DMSO treatment (Fig.5, $P < 0.05$, Student's t test).

Lovastatin down-regulates the melanoma cell adhesion molecule

To investigate the effect of lovastatin on eMSCs markers, cells were treated with 1 μ M lovastatin for 72 hours and then, analyzed by flow cytometer. The results indicated that CD146 cell marker was down-regulated to 53% in response to 1 μ M lovastatin, compared to the untreated group (Fig.6, $P < 0.05$, Student's t test). In this respect, recent studies have shown that Melanoma Cell Adhesion Molecule (MCAM/CD146) was a key marker of endometrial stem/progenitor cells involved in the inflammation and angiogenesis procedures (47, 48).




Fig.5: Mesenchymal stem cells (MSCs) were plated in 24 well plates and either no treated, or treated with dimethyl sulfoxide (DMSO) or 1, 2 and 5 μ M lovastatin (diluted in DMSO) for 72 hours, followed by MTT test. Values are shown as living cells percentage relative to the control untreated cells with set at 100% in control values. Results expressed the mean \pm SD (n=3).
 *, $P < 0.05$ in comparison to untreated control in each groups.





Fig.6: Flow cytometry analysis of eMSCs markers treated with 1 µM lovastatin. The results indicated that CD146 cell marker was down-regulated to 53% in response to 1 µM lovastatin in comparison with untreated group. Data are from three experiments ± SD (n=3).
 *, P<0.05 in comparison to untreated control.

Discussion

Stem cell theory began the final advanced avenue for the etiology of endometriosis. A great number of studies demonstrated presence of the endometrial stem cells, not only from residing cells in the endometrium but also from reprogramming bone marrow MSCs (17). Feasibility of targeting stem cells was suggested to be as of the remarkable advancement to eliminate endometriosis (49).

This study evaluated the effect of lovastatin on eMSCs properties including differentiation and proliferation potential. In the current experiment, BMP2 activity was significantly augmented in eMSCs within three days after treatment with 2 μ M concentration of lovastatin. BMP2 activity was proved to be a marker of osteogenesis differentiation (38). Previous studies have demonstrated that lovastatin increased the level of BMP2 gene expression (50, 51). Moreover, BMP2 reportedly was down-regulated in endometriosis (29). In this respect, there was remarkable evidence showing that BMP2 signaling pathway plays a pivotal role in the decidualization (52, 53). The study carried out by van Kaam et al. (54) revealed that both ectopic and eutopic endometrium of patients suffering from endometriosis demonstrated a decreased capacity for differentiation, as well as decidualization and implantation.

In addition, RUNX2 expression level was significantly increased in the treatment of 2 and 5 μ M lovastatin, compared to the control group. RUNX2 is a major downstream mediator of BMP2, functioning and playing a critical role in the stromal differentiation and decidualization (55). Furthermore, MSCs differentiation towards osteogenic lineage was determined by definite group of elements (56). Among these factors, the first and highly specific marker was RUNX2. In this line, RUNX2 activated osteogenic differentiation by signaling pathways including BMP2 and TGF- β 1 (57, 58).

In the present study, expression of GATA2 was investigated in eMSCs after lovastatin treatment. In this case, GATA2 mRNA level was significantly decreased in response to the 5 μ M

lovastatin treatment, compared to the untreated control of patient group.

Increasingly, it was found that GATA2 expression, a member of the six zinc-finger family transcription factors, was essential for various tissues including urogenital and hematopoietic system and adipose maturation (59). Moreover, Kamata et al. (32) demonstrated that GATA2 could be one of the significant factors regulating differentiation of bone marrow MSCs toward adipocytes. Given the results of previous investigations (59, 32), reduction of GATA2 in response to lovastatin treatment might be in favor of decreased proliferation and increased differentiation potentials. However, this observation should be confirmed by other studies.

Furthermore, SYBR Green-based quantitative real time PCR method was performed to analyze DNA methylation level in eMSCs. The MethySYBR assay is a very sensitive, precise and less vulnerable to false positives (60). In this study, lovastatin treatment induced DNA demethylation and reactivation of BMP2 gene expression, which was suppressed by hypermethylation in the endometriosis. More importantly, we found demethylation of other methylated genes including RUNX2 in the endometriosis after treatment with lovastatin, implying more general effect on gene hypermethylation. Given the results of this study, it is not obvious how lovastatin inhibits DNMTs. Kodach et al. (18) showed that lovastatin has either little or no effect on DNMTs expression levels. Therefore, further investigations are required to evaluate the mechanism(s) by which lovastatin inhibit DNMTs. On the other hand, we found that lovastatin induced methylation of GATA2 factor. This result was in consistent with the latest data reported by MacLeod et al. (20), showing that lovastatin therapy is related to higher MTHFR methylation levels in a stroke group implying that statins can induce DNA methylation.

We also evaluated the effect of lovastatin on expression of MSCs markers. Some recent investigations have indicated that CD146 could be considered as a highly specific marker of

endometrial stem/progenitor cells (17, 61). In addition, Figueira et al. (13) used CD146 marker to identify mesenchymal stem cells for the first time. The eMSCs expressed typical MSC surface markers including CD44, CD90 and CD105.

In this study, flow cytometer data displayed that CD146 was reduced in response to lovastatin treatment in eMSCs, suggesting that CD146 could effectively be implicated in the endometriosis pathogenesis by activating the angiogenesis and inflammation (47). Additionally, CD146 is an endothelial cell adhesion molecule that is up-regulated in different types of malignant cell, such as ovarian cancer (62-65). A great number of experiments have suggested that CD146 induced angiogenesis, tumor growth and metastasis (66). Moreover, Flanagan et al. (67) showed that laminin-411 attached to CD146 enabling TH17 cell penetrate into the tissues and induce inflammation. Studies have revealed that lovastatin, which is a potent inhibitor for the expression of VEGF, plays a pivotal role in diminishing blood-vessel formation (68). Similarly, in the recent study, Jiang et al. (69) reported that CD146 interacts with VEGFR-2 in a tumor angiogenesis mechanism. In line with previous investigations, our research presents a new target of action for lovastatin, in inhibition of angiogenesis via suppressing CD146.

Based on the previous *in vitro* studies, doses of 1 to 5 μM were used for lovastatin treatment in MSCs (33, 38). In these experiments, mild growth stimulatory effects in eMSCs were derived from human endometrium, and endometriosis was observed at dose of 1 and 5 μM . In addition, Kupcsik et al. (38) revealed that lovastatin concentration at 10 μM is associated with cytotoxic effects and leads to detachment of eMSC from culture plate.

Zhou and Hu (23) showed that stem cell differentiation could be augmented by DNA demethylation, starting advancement for studying the induction of stem cell fate through epigenetic reprogramming. In this study, for the first time, we demonstrated that aberrant demethylation of CpG island promoter of *BMP2* occurred in endometriosis tissues. We

also provided a facet of molecular basis of the *BMP2* down-regulation in these tissues from the viewpoint of epigenetic disease. It is hoped that epigenetic reprogramming of *BMP2* becomes a helpful cue for the further research in the pathogenesis of endometriosis.

Conclusion

The proposed mechanisms of statins action on the endometriosis tissues are suppression of endometrial cells proliferation and apoptosis, reduction of oxidative stress and inflammation, and inhibition of the angiogenesis. Our study indicated that lovastatin treatment could increase osteogenic differentiation through up-regulation of *BMP2* and *RUNX2* mRNA expression. In addition, reduction of *GATA2* in response to lovastatin treatment might be in favor of increased adipogenic differentiation potentials. Expression of stem cell markers and subsequently stemness was also reduced in the eMSCs after lovastatin treatment.

Furthermore, consistent with the previous studies, our investigation revealed that lovastatin decreased angiogenesis and increased implantation and decidualization.

Several recent investigations have suggested that statins could have a pivotal role in the medical management of women suffering from endometriosis. They also offer clinical benefits without interfering in estrogen. Despite this fact, more clinical trials are needed to confirm the safety and effectiveness of this kind of treatment in endometriosis.

Acknowledgments

This study was financially supported by Research Deputy of Tarbiat Modares University. The authors thank Dr. Mashhadi khan for her technical supports. The authors declare that they have no conflict of interest.

References

1. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. *Best Pract Res Clin Obstet Gynaecol.* 2004; 18(2): 177-200.
2. Surrey ES, Schoolcraft WB. Management of endometriosis-associated infertility. *Obstet Gynecol Clin North Am.* 2003; 30(1): 193-208.
3. Kuohung W, Jones GL, Vitonis AF, Cramer DW, Kennedy SH, Thomas D, et al. Characteristics of patients

- with endometriosis in the United States and the United Kingdom. *Fertil Steril*. 2002; 78(4): 767-772.
4. Amsterdam LL, Gentry W, Jobanputra S, Wolf M, Rubin SD, Bulun SE. Anastrozole and oral contraceptives: a novel treatment for endometriosis. *Fertil Steril*. 2005; 84(2): 300-304.
 5. Giudice LC, Kao LC. Endometriosis. *Lancet*. 2004; 364(9447): 1789-1799.
 6. Juo SH, Wang TN, Lee JN, Wu MT, Long CY, Tsai EM. CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women. *Hum Reprod*. 2006; 21(6): 1498-1502.
 7. Juo SH, Wu R, Lin CS, Wu MT, Lee JN, Tsai EM. A functional promoter polymorphism in interleukin-10 gene influences susceptibility to endometriosis. *Fertil Steril*. 2009; 92(4): 1228-1233.
 8. Huang SY, Wang CJ, Soong YK, Wang HS, Wang ML, Lin CY, et al. Site-specific endometrial injury improves implantation and pregnancy in patients with repeated implantation failures. *Reprod Biol Endocrinol*. 2011; 9: 140
 9. Norrby K. Angiogenesis-new aspects relating to its initiation and control. *APMIS*. 1997; 105(6): 417-437.
 10. Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P, Mall G, et al. Uterine peristaltic activity and the development of endometriosis. *Ann N Y Acad Sci*. 2004; 1034: 338-355.
 11. Bulletti C, Coccia ME, Battistoni S, Borini A. Endometriosis and infertility. *J Assist Reprod Genet*. 2010; 27(8): 441-447.
 12. Gargett CE, Guo SW. Stem cells and clonality in endometriosis. In: Garcia-Velasco J, Rizk B, editors. *Endometriosis: current management and future trends*. New Delhi: Jaypee Brothers Medical Publishers; 2010; 308-317.
 13. Figueira PG, Abrão MS, Krikun G, Taylor HS. Stem cells in endometrium and their role in the pathogenesis of endometriosis. *Ann N Y Acad Sci*. 2011; 1221: 10-17.
 14. Kao AP, Wang KH, Chang CC, Lee JN, Long CY, Chen HS, et al. Comparative study of human eutopic and ectopic endometrial mesenchymal stem cells and the development of an in vivo endometriotic invasion model. *Fertil Steril*. 2011; 95(4): 1308-1315. e1.
 15. Wright JA, Sharpe-Timms KL. Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis. *Fertil Steril*. 1995; 63(5): 1094-1100.
 16. Friedlander RL. The treatment of endometriosis with Danazol. *J Reprod Med*. 1973; 10(4): 197-199.
 17. Yang J, Huang F. Stem cell and endometriosis: new knowledge may be producing novel therapies. *Int J Clin Exp Med*. 2014; 7(11): 3853-3858.
 18. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. *Gut*. 2011; 60(11): 1544-1553.
 19. Esfandiari N, Khazaei M, Ai J, Bielecki R, Gottlieb L, Ryan E, et al. Effect of a statin on an in vitro model of endometriosis. *Fertil Steril*. 2007; 87(2): 257-262.
 20. MacLeod M, Pogoryelova O, Horgan G, Haggarty P. Statin therapy is associated with higher MTHFR methylation levels in a stroke cohort. *Arterioscler Thromb Vasc Biol*. 2015; 35: A197.
 21. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW. Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. *Fertil Steril*. 2007; 87(1): 24-32.
 22. Xue Q, Lin Z, Yin P, Milad MP, Cheng YH, Confino E, et al. Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis. *J Clin Endocrinol Metab*. 2007. 92(8): 3261-3267.
 23. Zhou Y, Hu Z. Genome-wide demethylation by 5-aza-2'-deoxycytidine alters the cell fate of stem/progenitor cells. *Stem Cell Rev*. 2015; 11(1): 87-95.
 24. Jichan Nie, Xishi Liu, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. *Reprod Sci*. 2010; 17(11): 995-1005.
 25. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. *J Clin Oncol*. 2002; 20(10): 2429-2440.
 26. Wijermans P, Lübbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. *J Clin Oncol*. 2000; 18(5): 956-562.
 27. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. *Clin Cancer Res*. 2006; 12(19): 5777-5785.
 28. Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. *Gastroenterology*. 2007; 133(4): 1272-1281.
 29. Koike N, Higashiura Y, Akasaka J, Uekuri C, Ito F, Kobayashi H. Epigenetic dysregulation of endometriosis susceptibility genes (Review). *Mol Med Rep*. 2015; 12(2): 1611-1616.
 30. Li Q, Kannan A, Das A, Demayo FJ, Hornsby PJ, Young SL, et al. WNT4 acts downstream of BMP2 and functions via β -catenin signaling pathway to regulate human endometrial stromal cell differentiation. *Endocrinology*. 2013; 154(1): 446-457.
 31. Aghajanova L, Horcajadas JA, Esteban FJ, Giudice LC. The bone marrow-derived human mesenchymal stem cell: potential progenitor of the endometrial stromal fibroblast. *Biol Reprod*. 2010; 82(6): 1076-1087.
 32. Kamata M, Okitsu Y, Fujiwara T, Kanehira M, Nakajima S, Takahashi T, et al. GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells. *Haematologica*. 2014; 99(11): 1686-1696.
 33. Li X, Cui Q, Kao C, Wang GJ, Balian G. Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPAR gamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. *Bone*. 2003; 33(4): 652-659.
 34. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

- Cytotherapy. 2006; 8(4): 315-317.
35. Mohammadi Z, Tavakkol Afshari J, Keramati MR, Hamimidi Alamdari D, Ganjibakhsh M, Moradi Zarmehri A, et al. Differentiation of adipocytes and osteocytes from human adipose and placental mesenchymal stem cells. *Iran J Basic Med Sci.* 2015; 18(3): 259-266.
 36. Duijvestein M, Molendijk I, Roelofs H, Vos AC, Verhaar AP, Reinders ME, et al. Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. *Cytotherapy.* 2011; 13(9): 1066-1073.
 37. Kouhkan F, Alizadeh S, Kaviani S, Soleimani M, Pourfathollah AA, Amirzadeh N, et al. miR-155 down regulation by LNA inhibitor can reduce cell growth and proliferation in PC12 cell line. *Avicenna J Med Biotechnol.* 2011; 3(2): 61-66.
 38. Kupcsik L, Meurya T, Flury M, Stoddart M, Alini M. Statin-induced calcification in human mesenchymal stem cells is cell death related. *J Cell Mol Med.* 2009; 13(11-12): 4465-4473.
 39. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. *Clin Epigenetics.* 2013; 5(1): 3.
 40. Farshdousti Hagh M, Noruzinia M, Mortazavi Y, Soleimani M, Kaviani S, Mahmoodinia Maymand M. Epigenetic changes of RUNX2 and DLX5 genes in osteoblastic differentiation induced by zoledronic acid in mesenchymal stem cells. *Pathobiol Res.* 2011; 14(1): 59-69.
 41. Traupe T, Lang M, Goettsch W, Münter K, Morawietz H, Vetter W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. *J Hypertens.* 2002; 20(11): 2239-2245.
 42. Khazamipour N, Noruzinia M, Fatehmanesh P, Keyhaneh M, Pujol P. MTHFR promoter hypermethylation in testicular biopsies of patients with non-obstructive azoospermia: the role of epigenetics in male infertility. *Hum Reprod.* 2009; 24(9): 2361-2364.
 43. Husseiny MI, Kuroda A, Kaye AN, Nair I, Kandeel F, Ferreri K. Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes. *PLoS One.* 2012; 7(10): e47942.
 44. Wen XZ, Akiyama Y, Baylin SB, Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. *Oncogene.* 2006; 25(18): 2666-2673.
 45. Dyson MT, Roqueiro D, Monsivais D, Ercan CM, Pavone ME, Brooks DC, et al. Genome-wide DNA methylation analysis predicts an epigenetic switch for GATA factor expression in endometriosis. *PLoS Genet.* 2014; 10(3): e1004158.
 46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods.* 1983; 65(1-2): 55-63.
 47. Stalin J, Harhoury K, Hubert L, Subrini C, Lafitte D, Lisitzky JC, et al. Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomin. *J Biol Chem.* 2013; 288(13): 8991-9000.
 48. Schwab KE, Hutchinson P, Gargett CE. Identification of surface markers for prospective isolation of human endometrial stromal colony-forming cells. *Hum Reprod.* 2008; 23(4): 934-943.
 49. Taylor HS, Osteen KG, Bruner-Tran KL, Lockwood CJ, Krikun G, Sokalska A, et al. Novel therapies targeting endometriosis. *Reprod Sci.* 2011; 18(9): 814-823.
 50. Emmanuele L, Ortmann J, Doerflinger T, Traupe T, Barton M. Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. *Biochem Biophys Res Commun.* 2003; 302(1): 67-72.
 51. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. *Science.* 1999; 286(5446): 1946-1949.
 52. Li Q, Kannan A, Wang W, Demayo FJ, Taylor RN, Bagchi MK, et al. Bone morphogenetic protein 2 functions via a conserved signaling pathway involving Wnt4 to regulate uterine decidualization in the mouse and the human. *J Biol Chem.* 2007; 282(43): 31725-31732.
 53. Lee KY, Jeong JW, Wang J, Ma L, Martin JF, Tsai SY, et al. Bmp2 is critical for the murine uterine decidual response. *Mol Cell Biol.* 2007; 27(15): 5468-5478.
 54. van Kaam KJ, Delvoux B, Romano A, D'Hooghe T, Dunselman GA, Groothuis PG. Deoxyribonucleic acid methyltransferases and methyl-CpG-binding domain proteins in human endometrium and endometriosis. *Fertil Steril.* 2011; 95(4): 1421-1427.
 55. Athilakshmi K, Quanxi Li, Bagchi MK, Bagchi IC. The transcription factor Runx2 functions downstream of BMP2 to regulate decidualization in the mouse. *Biol Reprod.* 2009; 81 Suppl 1: 415.
 56. Ducy P, Karsenty G. Genetic control of cell differentiation in the skeleton. *Curr Opin Cell Biol.* 1998; 10(5): 614-619.
 57. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. *Mol Cell Biol.* 2000; 20(23): 8783-8792.
 58. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. *J Biol Chem.* 2003; 278(36): 34387-34394.
 59. Rubel CA, Franco HL, Jeong JW, Lydon JP, DeMayo FJ. GATA2 is expressed at critical times in the mouse uterus during pregnancy. *Gene Expr Patterns.* 2012; 12(5-6): 196-203.
 60. Lo PK, Watanabe H, Cheng PC, Teo WW, Liang X, Argani P, et al. MethySYBR, a novel quantitative PCR assay for the dual analysis of DNA methylation and CpG methylation density. *J Mol Diagn.* 2009; 11(5): 400-414.
 61. Zhang H, Zhang J, Wang Z, Lu D, Feng J, Yang D, et al. CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. *Oncol Lett.* 2013; 5(4): 1189-1194.
 62. Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. *Int J Cancer.* 2006; 119(8): 1920-1926.
 63. Feng G, Fang F, Liu C, Zhang F, Huang H, Pu C.

- CD146 gene expression in clear cell renal cell carcinoma: a potential marker for prediction of early recurrence after nephrectomy. *Int Urol Nephrol*. 2012; 44(6): 1663-1669.
64. Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, et al. CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. *Int J Mol Sci*. 2012; 13(5): 6399-6406.
 65. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. *Proc Natl Acad Sci USA*. 2012; 109(4): 1127-1132.
 66. Ouhtit A, Gaur RL, Abd Elmageed ZY, Fernando A, Thouta R, Trappey AK, et al. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. *Biochim Biophys Acta*. 2009; 1795(2): 130-136.
 67. Flanagan K, Fitzgerald K, Baker J, Regnstrom K, Gardai S, Bard F, et al. Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry in to the CNS. *PLoS One*. 2012; 7(7): e40443.
 68. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. *FEBS Lett*. 2001; 495(3): 159-166.
 69. Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. *Blood*. 2012; 120(11): 2330-2339.
-